The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates

Ophthalmology

Volumn 122, Issue 11, 2015, Pages 2311-2315.e1

  VanderBeek, Brian L ^a,b   Bonaffini, Sarah G ^c   Ma, Liyuan ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; STEROID; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; ENDOPHTHALMITIS; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; VITRECTOMY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; EYE INFECTIONS, BACTERIAL; FACTUAL DATABASE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; ODDS RATIO; RETINAL DISEASES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DATABASES, FACTUAL; DEXAMETHASONE; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; ODDS RATIO; RETINAL DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84955180837     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.07.005     Document Type: Article

References (20)

1. Holekamp NM, Liu Y, Yeh WS, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol 2014;157:825-833 e1.
2. Kiss S, Liu Y, Brown J, et al. Clinical utilization of antivascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol 2014;8:1611-21.
3. Lad EM, Hammill BG, Qualls LG, et al. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among Medicare beneficiaries. Am J Ophthalmol 2014;158:537-543.e2.
4. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29:875-912.
5. Francis JH, Marr BP, Brodie SE, et al. Tethered vitreous seeds following intravitreal melphalan for retinoblastoma. JAMA Ophthalmol 2014;132:1024-5.
6. Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 2013;3:32.
7. Tao Y, Jonas JB. Intravitreal triamcinolone. Ophthalmologica 2011;225:1-20.
8. Bhavsar AR, Ip MS, Glassman AR. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-6.
9. Westfall AC, Osborn A, Kuhl D, et al. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005;123:1075-7.
10. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6.
11. Jonas JB, Kreissig I, Spandau UH, et al. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579-80.
12. Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609-14.
13. Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, et al. Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Retina 2014;34:943-50.
14. Phase II Combination Steroid and Anti-VEGF for Persistent DME. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01945866?term=DRCR+protocol+U&rank=1.Accessed March 10, 2015.
15. Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (ORION). ClinicalTrials.gov 2013. Available at: https://clinicaltrials.gov/ct2/show/NCT01827722. Accessed March 10, 2015.
16. Bucher RS, Hall E, Reed DM, et al. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch Ophthalmol 2005;123:649-53.
17. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-91.
18. Lee AY, Akileswaran L, Tibbetts MD, et al. Identification of torque teno virus in culture-negative endophthalmitis by representational deep DNA sequencing. Ophthalmology 2015;122:524-30.
19. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014;121:2473-81.
20. Khurana RN, Palmer JD, Porco TC, Wieland MR. Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes. Ophthalmic Surg Lasers Imaging Retina 2015;46:56-61.